Radiopharm (RADX) news
Recent news
Radiopharm Theranostics - No dividends have been paid or declared by group for current FY
Radiopharm Theranostics has confirmed that no dividends have been paid or declared by the group for the current fiscal year (FY) as of the latest reporting period [1]. This aligns with the company’s ongoing strategic focus on reinvesting capital into research and development initiatives, as well as…
AInvest Wire · 3d agoRadiopharm Theranostics - FY prelim revenue from contracts with customers A$2.8 mln
Radiopharm Theranostics reported preliminary revenue of A$2.8 million for the fiscal year from contracts with customers, according to the company’s latest financial disclosure. This figure reflects the income generated through agreements with clients during the reporting period. The company has not…
AInvest Wire · 3d agoRadiopharm Theranostics - Prelim loss for the year attributable up 50.3% to A$55.15 mln for year ended 30 June 2026
AInvest Wire · 3d agoRadioPharm Theranostics to meet with U.S. FDA to align on pivotal Phase 3 trial design for Rad 101 in diagnosis of brain metastases
AInvest Wire · Aug 17, 2026RadioPharm Theranostics Ltd-RAD to meet with US FDA to align on RAD 101 Phase 3 trial
AInvest Wire · Aug 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.